Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

PD-1 Blockade Directed by ctDNA Delayed Recurrence in Mismatch Repair Deficient Solid Tumors After Surgery and Standard of Care

9:47
 
Share
 

Manage episode 482637361 series 1256601
Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

An interview with:

Yelena Y Janjigian MD, Medical Oncologist, Chief of Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York.

CHICAGO, USA—Patients with early-stage solid cancers with DNA mismatch repair-deficiency (also known as microsatellite instability) benefitted greatly if they received anti-programmed death-1 (PD-1) immunotherapy with pembrolizumab after surgery and standard of care if they tested positive for circulating tumor DNA (ctDNA).

These findings come from a phase two clinical trial reported at the 2025 Annual Meeting of the American Association for Cancer Research. Audio Journal of Oncology correspondent Peter Goodwin talked with first author of the study: Yelena Y Janjigian MD, Chief of the Gastrointestinal Oncology Service at Memorial Sloan-Kettering Cancer Center in New York.

INTERVIEW: Yelena Y Janjigian, MD

AACR ABSTRACT Title:

Circulating tumor DNA status to direct adjuvant immunotherapy for mismatch repair deficient tumors

  continue reading

51 episodes

Artwork
iconShare
 
Manage episode 482637361 series 1256601
Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

An interview with:

Yelena Y Janjigian MD, Medical Oncologist, Chief of Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York.

CHICAGO, USA—Patients with early-stage solid cancers with DNA mismatch repair-deficiency (also known as microsatellite instability) benefitted greatly if they received anti-programmed death-1 (PD-1) immunotherapy with pembrolizumab after surgery and standard of care if they tested positive for circulating tumor DNA (ctDNA).

These findings come from a phase two clinical trial reported at the 2025 Annual Meeting of the American Association for Cancer Research. Audio Journal of Oncology correspondent Peter Goodwin talked with first author of the study: Yelena Y Janjigian MD, Chief of the Gastrointestinal Oncology Service at Memorial Sloan-Kettering Cancer Center in New York.

INTERVIEW: Yelena Y Janjigian, MD

AACR ABSTRACT Title:

Circulating tumor DNA status to direct adjuvant immunotherapy for mismatch repair deficient tumors

  continue reading

51 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play